Rose G
Department of Epidemiology, London School of Hygiene and Tropical Medicine, England.
Am Heart J. 1987 Oct;114(4 Pt 2):1013-7. doi: 10.1016/0002-8703(87)90602-8.
The main threat to patients with mild to moderate hypertension is coronary heart disease (CHD), but controlled trials of antihypertensive drug therapy have given disappointing results: overall, the reduction in CHD mortality (11%) and morbidity (10%) were small and nonsignificant. Recent trials comparing a beta blocker with other antihypertensive drugs have not shown the "cardioprotection" expected from their pharmacologic actions and from their effectiveness after myocardial infarction; but two large trials have suggested some reduction in CHD among male nonsmokers. Relaxation with biofeedback possibly lowers CHD risk. Although the trials indicate that drugs generally do little to reduce CHD in hypertensive patients, control of smoking and serum cholesterol may be more effective.
轻度至中度高血压患者面临的主要威胁是冠心病（CHD），但抗高血压药物治疗的对照试验结果令人失望：总体而言，冠心病死亡率（11%）和发病率（10%）的降低幅度很小且无统计学意义。最近比较β受体阻滞剂与其他抗高血压药物的试验并未显示出其药理作用以及心肌梗死后有效性所预期的“心脏保护作用”；但两项大型试验表明，男性非吸烟者的冠心病发病率有所降低。生物反馈放松疗法可能会降低冠心病风险。尽管试验表明，药物通常对降低高血压患者的冠心病作用不大，但控制吸烟和血清胆固醇可能更有效。
